Surabhi Dangi-Garimella, PhD

A new single-patient case study, published in the New England Journal of Medicine, has raised the possibility of using CAR-T cells in the treatment of glioblastoma, an aggressive form of brain tumor.

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity.

Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).

Distinct genetic signatures can help distinguish responders from nonresponders of chimeric antigen receptor (CAR) T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.

Use of stereotactic body radiation therapy improved survival in elderly patients diagnosed with early-stage non-small cell lung cancer by about 20% over a decade.

An early-phase, dose-finding study using a defined composition of chimeric antigen receptor-T cells, in patients with non-Hodgkin lymphoma, shows promise.

At the annual meeting of the American Society of Clinical Oncology, results were presented from a phase 1/2 trial in which patients with relapsed or refractory CD19+ B-cell malignancies were treated with CD19 CAR-T cells.

A small study in 30 patients with advanced B-cell acute lymphoblastic leukemia has further strengthened the faith in the potential of chimeric antigen receptor or CAR-T cell therapy.

Two months after being granted a Breakthrough Therapy designation by the FDA for metastatic renal cell carcinoma (mRCC), nivolumab was today approved by regulators for treating mRCC patients who have failed a certain type of prior therapy.

After melanoma and non-small cell lung cancer, the FDA has granted Breakthrough Therapy status to pembrolizumab in advanced colorectal cancer patients with mismatched repair deficiency.

Today, Merck announced that Keytruda has been granted breakthrough therapy designation for treating patients with epidermal growth factor receptor mutation-negative and anaplastic lymphoma kinase rearrangement-negative non-small cell lung cancer (NSCLC).

Stem cell therapy has gained increasing traction in various therapeutic areas, from cancer to diabetes to ocular regeneration.